["Streptozotocin (STZ) is widely used to induce oxidative damage and to impair glucose metabolism, apoptosis, and tau/Aβ pathology, eventually leading to cognitive deficits in both in vitro and in vivo models of Alzheimer's disease (AD). In this study, we constructed a cell-based platform using STZ to induce stress conditions mimicking the complicated pathologies of AD in vitro, and evaluated the anti-amyloid effects of a small molecule, N-(1,3-benzodioxol-5-yl)-2-[5-chloro-2-methoxy(phenylsulfonyl)anilino]acetamide (LX2343) in the amelioration of cognitive deficits in AD model mice.", 'Cell-based assays for screening anti-amyloid compounds were established by assessing Aβ accumulation in HEK293-APP', 'LX2343 (5-20 μmol/L) dose-dependently decreased Aβ accumulation in HEK293-APP'] Does small molecule LX2343 ameliorate cognitive deficits in AD model mice by targeting both amyloid β production and clearance?